About: Sargramostim

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Sargramostim Goto Sponge NotDistinct Permalink

An Entity of Type : owl:Class, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	Class
rdfs:label	Sargramostim
rdfs:subClassOf	Recombinant Granulocyte-Macrophage Colony-Stimulating Factor
Concept_In_Subset	FDA Established Names and Unique Ingredient Identifier Codes Terminology
Semantic_Type	Amino Acid, Peptide, or Protein Pharmacologic Substance
Preferred_Name	Sargramostim
UMLS_CUI	C0216231
CAS_Registry	123774-72-1
Accepted_Therapeutic_Use_For	Melanoma; Neutropenia-chemotherapy induced
In_Clinical_Trial_For	Neuroblastoma; Non-Small Cell Lung cancer; Ovarian epithelial cancer; Pancreatic cancer; Prostate cancer; Pulmonary Alveolar Proteinosis; Renal cell cancer; Rhabdomyosarcoma; Sarcoma; Unspecified solid tumor Aplastic Anemia; Bladder cancer; Brain tumor; Breast cancer; Colorectal cancer; Gastric cancer; Graft versus Host disease; Hematologic cancer; Malignant glioma; Melanoma; Multiple myeloma; Myelodysplastic syndrome; Myeloproliferative disease
FDA_UNII_Code	5TAA004E22
Contributing_Source	FDA
ALT_DEFINITION	A substance that helps make more white blood cells, especially granulocytes, macrophages, and cells that become platelets. It is a cytokine that is a type of hematopoietic (blood-forming) agent.NCI-GLOSS
PDQ_Open_Trial_Search_ID	40566
PDQ_Closed_Trial_Search_ID	40566
Legacy_Concept_Name	Sargramostim
FULL_SYN	SARGRAMOSTIMPTFDA5TAA004E22 SagramostimSYNCI SargramostimPTNCI SargramostatinSYNCI sargramostimPTNCI-GLOSSCDR0000045304 23-L-Leucinecolony-Stimulating Factor 2SYNCI LeukineBRNCI ProkineBRNCI DRG-0012CNNCI rhu GM-CFSABNCI
DEFINITION	A recombinant therapeutic agent chemically identical to endogenous human GM-CSF except a leucine substitution in position 23. Binding to specific cell surface receptors, sargramostim modulates the proliferation and differentiation of a variety of hematopoietic progenitor cells with some specificity towards stimulation of leukocyte production and may reverse treatment-induced neutropenias. This agent also promotes antigen presentation, up-regulates antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function; it may also augment host antitumoral immunity.NCI
code	C1492
is someValuesFrom of	nodeID://b642639 nodeID://b646204 nodeID://b646212 nodeID://b647148 nodeID://b647662 nodeID://b647673 nodeID://b647696 nodeID://b647702 nodeID://b647707 nodeID://b647711 nodeID://b647737 nodeID://b647741 nodeID://b650809 nodeID://b650847 nodeID://b651807 nodeID://b651892 nodeID://b656765 nodeID://b656859 nodeID://b656863 nodeID://b656889 nodeID://b656963 nodeID://b657057 nodeID://b657072 nodeID://b657099 nodeID://b657202 nodeID://b657219 nodeID://b657316 nodeID://b657381 nodeID://b659612 nodeID://b659677 nodeID://b659705 nodeID://b659783 nodeID://b659820 nodeID://b659833 nodeID://b659855 nodeID://b659991 nodeID://b660042 nodeID://b660062 nodeID://b660166 nodeID://b660206 nodeID://b660416 nodeID://b662786 nodeID://b662803 nodeID://b662848 nodeID://b662922 nodeID://b662936 nodeID://b662960 nodeID://b662976 nodeID://b663114 nodeID://b663176 nodeID://b663196 nodeID://b663323 nodeID://b663508 nodeID://b663607 nodeID://b663645 nodeID://b663661 nodeID://b663732 nodeID://b663928 nodeID://b663949 nodeID://b663985 nodeID://b664154 nodeID://b664284 nodeID://b664368 nodeID://b664395 nodeID://b665919 nodeID://b666424 nodeID://b666634 nodeID://b666666 nodeID://b666711 nodeID://b667154

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 52 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software